Evotec and Exscientia Initiate Human Clinical Trials of their Novel Immuno-Oncology Drug
Shots:
- The companies initiate the clinical trial of A2a receptor antagonist- co-developed by Exscientia and Evotec utilizing Exscientia's AI-design platform- Centaur Chemist
- Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development
- The A2a receptor is currently in development for adult patients with advanced solid tumors and has the potential to show high selectivity for the targeted receptor
Ref: Evotec | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com